Home
Team
Blog
Experts
Careers
Projects
Code of Conduct
Press
Publications
Contact Us
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How would you treat CML and CLL that occurred together?
Related Questions
How would you manage persistent severe neutropenia from obinutuzumab in a 1st line CLL patient prior to venetoclax initiation?
What is your approach to the management of treatment-related MDS?
For frail patients with cardiac co-morbidities and relapsed CLL with high cytogenetic risk, what are some considerations for using continuous acalabrutinib over fixed duration therapies such as venetoclax/rituximab?
How do you define “induction failure” in ALL for an adult patient on hyperCVAD if goal is to proceed to transplant?
How do you manage hypophosphatemia associated with CML TKIs?
How would you manage a CLL patient who experienced severe infusion reactions with rituximab and has exhausted all other options?
When would you use acalabrutinib in combination with obinutuzumab vs acalabrutinib alone in upfront CLL treatment?
How do you decide between CPX-351 and HMA + Venetoclax in treating transplant eligible AML-MRC?
Do you recommend treatment for CLL patients with biopsy proven infiltrative lesions in the liver without hepatic dysfunction or hepatomegaly?
How do you approach conversations regarding discontinuation of transfusions in patients with advanced hematologic malignancies who are otherwise appropriate for hospice?
